---
title: >-
  Correlation between achieving SALT 20 score and clinician- and
  patient-reported outcomes among patients diagnosed with alopecia areata in the
  US: An assessment from the TARGET-DERM AA registry.
description: >-
  Explore this publication on real-world evidence: Correlation between achieving
  SALT 20 score and clinician- and patient-reported outcomes among patients…
date: '2025-01-01'
category: Publications
tags:
  - Maui Derm Conference
  - Poster Presentation
  - R&D
  - Care
  - Dermatology
  - Alopecia Areata (AA)
  - Pharma Partner
  - Health System Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/maui-derm-conference/correlation-between-achieving-salt-20-score-and-clinician/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: correlation-between-achieving-salt-20-score-and-clinician
id: 4pOw84dVr1o6xGhDFeQbkw
contentType: article
---

## Challenge

SALT 20—a clinically meaningful hair regrowth threshold—had not been validated against patient-reported outcomes in a real-world AA cohort, leaving uncertainty about whether achieving this threshold translates into improvements in patient-experienced disease burden across AA-specific and generic PRO instruments.

## Solution

The TARGET-DERM AA registry was used to compare changes in CGI-AA, AAPPO, P-SAT, and PROMIS anxiety/depression scores between patients who achieved SALT 20 and those who did not, providing the first real-world validation of SALT 20 as a clinically meaningful PRO-anchored response threshold.

## Impact

Demonstrating that SALT 20 achievement is associated with significant improvements across multiple clinician- and patient-reported AA outcomes provides the clinical meaningfulness evidence needed to justify SALT 20 as a regulatory endpoint in AA trials and supports AbbVie's label strategy for rinvoq and other JAK inhibitors.

### [Julie M. Crawford](/people/julie-crawford/)